Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.

TitleComparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.
Publication TypeJournal Article
Year of Publication2015
AuthorsTyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M
JournalJ Mol Diagn
Volume17
Issue4
Pagination374-81
Date Published2015 Jul
ISSN1943-7811
KeywordsClinical Trials, Phase III as Topic, Female, Formaldehyde, Gene Expression Profiling, Humans, Male, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms, Paraffin Embedding, Prospective Studies, Prostatic Neoplasms, Randomized Controlled Trials as Topic, RNA, Messenger, RNA, Neoplasm, Tissue Fixation
Abstract

Archival formalin-fixed, paraffin-embedded (FFPE) tissue specimens represent a readily available but largely untapped resource for gene expression profiling-based biomarker discovery. Several technologies have been proposed to cope with the bias from RNA cross-linking and degradation associated with archival specimens to generate data comparable with RNA from fresh-frozen materials. Direct comparison studies of these RNA expression platforms remain rare. We compared two commercially available platforms for RNA expression profiling of archival FFPE specimens from clinical studies of prostate and ovarian cancer: the Affymetrix Human Gene 1.0ST Array following whole-transcriptome amplification using the NuGen WT-Ovation FFPE System V2, and the NanoString nCounter without amplification. For each assay, we profiled 7 prostate and 11 ovarian cancer specimens, with a block age of 4 to 21 years. Both platforms produced gene expression profiles with high sensitivity and reproducibility through technical repeats from FFPE materials. Sensitivity and reproducibility remained high across block age within each cohort. A strong concordance was shown for the transcript expression values for genes detected by both platforms. We showed the biological validity of specific gene signatures generated by both platforms for both cohorts. Our study supports the feasibility of gene expression profiling and large-scale signature validation on archival prostate and ovarian tumor specimens using commercial platforms. These approaches have the potential to aid precision medicine with biomarker discovery and validation.

DOI10.1016/j.jmoldx.2015.02.002
Alternate JournalJ Mol Diagn
PubMed ID25937617
PubMed Central IDPMC4483460
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
CA136578 / CA / NCI NIH HHS / United States
R01CA131945 / CA / NCI NIH HHS / United States
5R01CA142832-05 / CA / NCI NIH HHS / United States
5R01CA141298 / CA / NCI NIH HHS / United States
1RC4CA156551-01 / CA / NCI NIH HHS / United States
R01 CA131945 / CA / NCI NIH HHS / United States
P50CA90381 / CA / NCI NIH HHS / United States
R01 CA142832 / CA / NCI NIH HHS / United States
CA090381 / CA / NCI NIH HHS / United States
R01 CA136578 / CA / NCI NIH HHS / United States
RC4 CA156551 / CA / NCI NIH HHS / United States
R01 CA141298 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700